Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine

S. J. Cryz, Harris Goldstein, M. Pettoello-Mantovani, A. Kim, E. Fürer, J. U. Que, T. Hasler, Arye Rubinstein

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To enhance the potential efficacy of peptide-based vaccines for human immunodeficiency virus-1 (HIV-1), a principal neutralizing domain (PND) peptide (KRIHIGPGRAFYT) (HIV-1MN) was covalently coupled to Pseudomonas aeruginosa toxin A (TA). Immunization of guinea-pigs with this conjugate vaccine, in the absence of an adjuvant, engendered a high-affinity antibody response to the homologous HIV-1MN PND peptide and to analogous peptides from variant strains of HIV-1. A substantial proportion of such antibodies was directed to the conserved GPGRAF motif. Anti-PND peptide antibodies were capable of neutralizing the homologous strain, HIV-1MN, in addition to two heterologous (RF, IIIB) variants, as determined either by inhibition of syncytia formation or by suppression of p24 antigen production in cultured cells. Therefore, the method of conjugation used preserved critical neutralizing epitopes expressed by the PND peptide. Monovalent or polyvalent PND-TA conjugates, which meet all safety criteria for human use, are a promising approach towards the development of an acquired immunodeficiency syndrome (AIDS) vaccine.

Original languageEnglish (US)
Pages (from-to)67-71
Number of pages5
JournalVaccine
Volume13
Issue number1
DOIs
StatePublished - 1995

Fingerprint

Immunotoxins
Conjugate Vaccines
Human immunodeficiency virus 1
neutralization
HIV-1
toxins
peptides
vaccines
HIV
Subunit Vaccines
Antibodies
Giant Cells
Pseudomonas aeruginosa
Antibody Formation
Epitopes
Cultured Cells
Immunization
Guinea Pigs
Acquired Immunodeficiency Syndrome
Vaccines

Keywords

  • Human immunodeficiency virus-1
  • peptide-toxin A conjugate
  • principal neutralizing domain

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Immunology
  • Microbiology
  • Virology

Cite this

Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine. / Cryz, S. J.; Goldstein, Harris; Pettoello-Mantovani, M.; Kim, A.; Fürer, E.; Que, J. U.; Hasler, T.; Rubinstein, Arye.

In: Vaccine, Vol. 13, No. 1, 1995, p. 67-71.

Research output: Contribution to journalArticle

Cryz, S. J. ; Goldstein, Harris ; Pettoello-Mantovani, M. ; Kim, A. ; Fürer, E. ; Que, J. U. ; Hasler, T. ; Rubinstein, Arye. / Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine. In: Vaccine. 1995 ; Vol. 13, No. 1. pp. 67-71.
@article{e5c554b62f6c4014b7b51c4ba80ff7b1,
title = "Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine",
abstract = "To enhance the potential efficacy of peptide-based vaccines for human immunodeficiency virus-1 (HIV-1), a principal neutralizing domain (PND) peptide (KRIHIGPGRAFYT) (HIV-1MN) was covalently coupled to Pseudomonas aeruginosa toxin A (TA). Immunization of guinea-pigs with this conjugate vaccine, in the absence of an adjuvant, engendered a high-affinity antibody response to the homologous HIV-1MN PND peptide and to analogous peptides from variant strains of HIV-1. A substantial proportion of such antibodies was directed to the conserved GPGRAF motif. Anti-PND peptide antibodies were capable of neutralizing the homologous strain, HIV-1MN, in addition to two heterologous (RF, IIIB) variants, as determined either by inhibition of syncytia formation or by suppression of p24 antigen production in cultured cells. Therefore, the method of conjugation used preserved critical neutralizing epitopes expressed by the PND peptide. Monovalent or polyvalent PND-TA conjugates, which meet all safety criteria for human use, are a promising approach towards the development of an acquired immunodeficiency syndrome (AIDS) vaccine.",
keywords = "Human immunodeficiency virus-1, peptide-toxin A conjugate, principal neutralizing domain",
author = "Cryz, {S. J.} and Harris Goldstein and M. Pettoello-Mantovani and A. Kim and E. F{\"u}rer and Que, {J. U.} and T. Hasler and Arye Rubinstein",
year = "1995",
doi = "10.1016/0264-410X(95)80013-4",
language = "English (US)",
volume = "13",
pages = "67--71",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine

AU - Cryz, S. J.

AU - Goldstein, Harris

AU - Pettoello-Mantovani, M.

AU - Kim, A.

AU - Fürer, E.

AU - Que, J. U.

AU - Hasler, T.

AU - Rubinstein, Arye

PY - 1995

Y1 - 1995

N2 - To enhance the potential efficacy of peptide-based vaccines for human immunodeficiency virus-1 (HIV-1), a principal neutralizing domain (PND) peptide (KRIHIGPGRAFYT) (HIV-1MN) was covalently coupled to Pseudomonas aeruginosa toxin A (TA). Immunization of guinea-pigs with this conjugate vaccine, in the absence of an adjuvant, engendered a high-affinity antibody response to the homologous HIV-1MN PND peptide and to analogous peptides from variant strains of HIV-1. A substantial proportion of such antibodies was directed to the conserved GPGRAF motif. Anti-PND peptide antibodies were capable of neutralizing the homologous strain, HIV-1MN, in addition to two heterologous (RF, IIIB) variants, as determined either by inhibition of syncytia formation or by suppression of p24 antigen production in cultured cells. Therefore, the method of conjugation used preserved critical neutralizing epitopes expressed by the PND peptide. Monovalent or polyvalent PND-TA conjugates, which meet all safety criteria for human use, are a promising approach towards the development of an acquired immunodeficiency syndrome (AIDS) vaccine.

AB - To enhance the potential efficacy of peptide-based vaccines for human immunodeficiency virus-1 (HIV-1), a principal neutralizing domain (PND) peptide (KRIHIGPGRAFYT) (HIV-1MN) was covalently coupled to Pseudomonas aeruginosa toxin A (TA). Immunization of guinea-pigs with this conjugate vaccine, in the absence of an adjuvant, engendered a high-affinity antibody response to the homologous HIV-1MN PND peptide and to analogous peptides from variant strains of HIV-1. A substantial proportion of such antibodies was directed to the conserved GPGRAF motif. Anti-PND peptide antibodies were capable of neutralizing the homologous strain, HIV-1MN, in addition to two heterologous (RF, IIIB) variants, as determined either by inhibition of syncytia formation or by suppression of p24 antigen production in cultured cells. Therefore, the method of conjugation used preserved critical neutralizing epitopes expressed by the PND peptide. Monovalent or polyvalent PND-TA conjugates, which meet all safety criteria for human use, are a promising approach towards the development of an acquired immunodeficiency syndrome (AIDS) vaccine.

KW - Human immunodeficiency virus-1

KW - peptide-toxin A conjugate

KW - principal neutralizing domain

UR - http://www.scopus.com/inward/record.url?scp=0028795780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028795780&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(95)80013-4

DO - 10.1016/0264-410X(95)80013-4

M3 - Article

VL - 13

SP - 67

EP - 71

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -